Insmed/INSM

$24.27

-0.21%
-
1D1W1MYTD1YMAX

About Insmed

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Ticker

INSM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

William Lewis

Employees

912

Headquarters

Bridgewater, United States
Website
insmed.com

Insmed Metrics

BasicAdvanced
$3.61B
Market cap
-
P/E ratio
-$5.35
EPS
0.93
Beta
-
Dividend rate
$3.61B
0.93483
$32.00
$17.41
1.67M
4.118
3.749
-17.21%
-50.2%
-58.32%
11.837
24.39%
-37.6%
22.9%

What the Analysts think about Insmed

Analyst Ratings

Majority rating from 16 analysts.
Buy

Price Targets

Average projection from 15 analysts.
80.76% upside
High $55.00
Low $35.00
$24.27
Current price
$43.87
Average price target

Insmed Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-222.48% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$83.6M
5.82%
Net income
$-186M
17.05%
Profit margin
-222.48%
10.62%

Insmed Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.68%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.17
-$1.78
-$1.11
-$1.28
-
Expected
-$1.11
-$1.13
-$1.13
-$1.15
-$1.23
Surprise
5.17%
57.4%
-1.94%
11.68%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Insmed stock?

Insmed (INSM) has a market cap of $3.61B as of April 22, 2024.

What is the P/E ratio for Insmed stock?

The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of April 22, 2024.

Does Insmed stock pay dividends?

No, Insmed (INSM) stock does not pay dividends to its shareholders as of April 22, 2024.

When is the next Insmed dividend payment date?

Insmed (INSM) stock does not pay dividends to its shareholders.

What is the beta indicator for Insmed?

Insmed (INSM) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Insmed stock price target?

The target price for Insmed (INSM) stock is $43.87, which is 80.76% above the current price of $24.27. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Insmed stock

Buy or sell Insmed stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing